Bioplus Life Sciences, the manufacturer of Solo™ Sucralose based in Bangalore India, has formed a strategic exclusive European marketing and distribution alliance with Prinsen, a renowned manufacturer of high-quality food products across Europe.
The agreement will see Prinsen become the representative of the Solo private label offering to large grocers, pharmacy chains and marketing companies of Solo™ Sucralose retail private label sweeteners in the UK and Western Europe. Solo™ Sucralose is available to the retail trade in tablet, sachet, stick and a granular form for the private label and branded product markets. Prinsen will market Solo™ Sucralose as a viable high-quality private label alternative for their existing customer base, as well as using this offering to attract new customers into the business.
BioPlus and Prinsen will offer Solo™ Sucralose as a high-purity alternative to many of the existing products currently commercially available. Solo™ Sucralose meets or exceeds all of the analytical specifications formally established and published by the various global regulatory authorities including FDA and The European Commission (EU).
Solo™ Sucralose conforms to all of the analytical specifications as laid out by the FDA and The EU Commission for the commercial sale and use of sucralose as detailed in the specifications published by the EU, USP, FCC and JECFA as well as the Joint Subcommittee on Toxicity and Food Additives in Japan for total product purity as well as all related sensory criteria.
The availability of a new, reliable, high-quality source of sucralose produced by BioPlus at its emission-free, state-of-the-art manufacturing facility in India will eliminate the quality and legal risks associated with sourcing and using sucralose being marketed by suppliers other than Tate & Lyle.
BioPlus believes that significant quality issues exist for users of non-patented suppliers of sucralose, related to product quality and specifications, total purity, non-sucralose contaminants and actual production site traceability.
Furthermore, in addition to the potential risk of IP indemnification there is the prospect of future patent and IP infringement issues when the 30 BioPlus patent applications are issued over the next 12-24 months.
Joe Zannoni VP for BioPlus Life Sciences comments, “BioPlus Life Sciences is delighted to partner with Prinsen for the marketing and distribution of Solo™ Sucralose for own label grocery brands in the UK and Europe. Prinsen has an 80 year history in the private label market and an enviable reputation in this marketplace. Prinsen offers BioPlus the opportunity to leverage long standing supply relationships with many of Europe’s leading grocery companies, as well as established distribution and logistics infrastructure and customer support and service staff.”
Peter Tattersall, MD of Prinsen UK, comments, “The Prinsen senior management team has been very impressed with the overall project planning and implementation that culminated in Bioplus’ entering the Sucralose market. Many of our existing customers need the supply assurance that comes with a legitimate second source of Sucralose and we are pleased to help meet this need. Prinsen has an extensive retail sweetener customer base and we therefore feel that we are well positioned to assist Bioplus in bringing Solo™ Sucralose to market as a private label product. We are delighted to add this product to our existing portfolio and look forward to continuing to offer an exceptional level of service to both existing and new customers.”
Prinsen (UK) Limited
Peter Tattersall
T. +44 (0) 1234 345066
E.mail: ptattersall@prinsen.nl
Comments are closed.